Fig. 1. CONSORT flow diagram.

MRI scanning was performed at baseline (T0), after the 4-week (oxytocin/placebo) treatment (T1), and at two follow-up sessions, 4 weeks (T2) and 1 year after cessation of the treatment (T3). One participant of the oxytocin group discontinued the intervention after 1 week due to self-termination (unrelated to the treatment). One patient of the placebo group completed the 4-week treatment, but was excluded from the MRI analyses due to excessive in-scanner head motion (mean framewise displacement exceeding 0.5 mm, requiring removal of 98.5% of images). Six additional participants (three oxytocin and three placebo) were lost for the follow-up session T3.